StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
Genocea Biosciences has a 12-month low of $0.00 and a 12-month high of $0.00. The firm has a market capitalization of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- Retail Stocks Investing, Explained
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- The Significance of Brokerage Rankings in Stock Selection
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- Profitably Trade Stocks at 52-Week Highs
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.